18/19F-LABELLED COMPOUNDS WHICH TARGET THE PROSTATE SPECIFIC MEMBRANE ANTIGEN
This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each Rl is an anionic group, L is a linker and R2BF3 is - N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 06. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
BENARD FRANCOIS [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-03-06, Last update posted on www.tib.eu: 2024-03-19, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
EP3400229 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA00055328X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA00055328X | ||
| 003 | DE-627 | ||
| 005 | 20240322140428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA00055328X | ||
| 035 | |a (EPA)EP3400229 | ||
| 035 | |a (EPA)59273084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a BENARD FRANCOIS |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 18/19F-LABELLED COMPOUNDS WHICH TARGET THE PROSTATE SPECIFIC MEMBRANE ANTIGEN |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-03-06, Last update posted on www.tib.eu: 2024-03-19, Last updated: 2024-03-22 | ||
| 520 | |a This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each Rl is an anionic group, L is a linker and R2BF3 is - N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed. | ||
| 650 | 4 | |a C07F: Acyclic, carbocyclic, or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium (metal-containing porphyrins c07d0487220000;macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LIN KUO-SHYAN |4 aut | |
| 700 | 0 | |a PERRIN DAVID |4 aut | |
| 700 | 0 | |a LIU ZHIBO |4 aut | |
| 700 | 0 | |a KUO HSIOU-TING |4 aut | |
| 700 | 0 | |a PAN JINHE |4 aut | |
| 700 | 0 | |a ROXIN ARON |4 aut | |
| 700 | 0 | |a LEPAGE MATHIEU |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 06. März |
| 773 | 1 | 8 | |g year:2024 |g day:06 |g month:03 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/59273084/publication/EP3400229A1?q=EP3400229 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 06 |c 03 | ||